K9 and equine joint health food supplement and method of administering

Abstract

Kolla2 powder compositions, methods of preparing the compositions, and use of the compositions in treating degenerative joint diseases, joint defects, hip displasia, and osteoarthritis. The compositions are orally administered to K9's and equines in need of cartilage cell repair in a daily dietary food supplement.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application is a Continuation-in-Part of U.S. Ser. No. 09 / 768,141, filed on Jan. 24, 2001, and the disclosure of which is incorporated herein by reference to the extent necessary to a fully and complete enabling disclosure of this present invention.FIELD OF THE INVENTION [0002] The present invention provides a composition useful as a dietary food supplement for treating existing or incipient or prospective arthritis by oral consumption of the food supplement by mammals. Particularly, the present invention provides a composition, method of making, and method of using, which is particularly useful in preventing, delaying, or treating arthritis and other joint health maladies in mammals including dogs (i.e., K9's) and horses (i.e., equines). The inventive composition and method of use provides for extraction from desiccated avian sternal cartilage of collagen type II powder, a method of manufacturing the composition, and its use as a f...

AI Technical Summary

Benefits of technology

[0014] The present invention provides a desiccated avian sternal cartilage collagen type II powder, the powder having an average molecular weight of between about 45,000 and 65,000 daltons. Preferably, the powder has an average molecular weight of about 50,000 daltons. In one aspect of this preferred art, the powder is obtained from desiccated young avian sternal cartilage. Preferably, the avian sternal cartilage is collected from 4-8 week old chicks. The powder is partially water-soluble and the composition comprises 20% to 30% mucopolysaccaride (carbohydrate) and 65% to 70% collagen type II (protein) and the content of 1% to 3% lipids is part of the powder composition. The present invention also provides a method of helping cartilage formation in mammals with connective tissue disorders and degenerative joint diseases, comprising orally administering to the individual an effective daily cartilage-inducing amount of the powder.

Problems solved by technology

It results from the natural wear and tear of joint cartilage.

In particular, dogs (i.e., K9's) and horses (i.e., equines) both suffer from joint conditions which impact their quality of life.

The problems associated with hip displasia stem from an imbalance in the muscle mass and mechanical forces which are centered on the hip joint.

This imbalance is associated with excessive laxity (looseness) which is usually the result of a shallow acetabulum (cup).

This results in pain and eventually to the formation of abnormal calcium deposits, bone spurs and / or arthritis.

Continued use of the affected joint causes abnormal wear on the joint's cartilage surfaces leading to further damage and a self-perpetuating degenerative process ensues.

Abnormal bony development of the hip joint often results, and inflammation and irritation (arthritis) ultimately cause mild to severe lameness.

This results in the exposure of subchondral bone and pain nerve fibers resulting in significant joint pain.

Once degenerative joint disease is present, there a fewer treatment options available.

In horses (i.e., equine), the joint disorders frequently result from overuse, and over-training.

That is, thoroughbred horses frequently are subjected to a rigorous training regimen from an early age, and this subjects the animals joints to great stresses.

With joint deterioration progressing generally according to the amount of use and stress, it is to be expected that these animals will eventually experience joint deterioration and disease.

Images